source
- FDA agrees to revisit rare blood cancer drug Ebvallo after companies address concernsTwo companies developing a therapy for a rare blood cancer have reached an agreement with the FDA to address the agency’s concerns about their drug Ebvallo. The FDA had previously rejected Ebvallo…
- AI-generated fake citations surge, study finds they are polluting scientific literatureA new study published in The Lancet reports a sharp rise in fabricated citations that do not correspond to real papers, threatening the reliability of the scientific record. The researchers found…